Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D Investment by 9 Major Companies Increases 3.5% in First 6 Months
January 22, 2001
- SCRIP Tokyo Office Moves
January 22, 2001
- Daiichi Pure Chemicals Starts Contract SNP Analysis Services
January 22, 2001
- Merger with Mitsui Pharm Strengthens Schering Group's Product Line
January 22, 2001
- 15 Researchers Win AstraZeneca Asthma Research Award
January 22, 2001
- Cancer to Be Next 'Franchise' Area Following CNS, GI Fields: Mr Shinoda of Eisai
January 22, 2001
- New Kosei-Rodosho Inaugurated on Jan. 6
January 22, 2001
- Kyushu Univ. Opens Master's Course to Train Specialized Medical Professionals
January 22, 2001
- National Organization Proposed to Train CRCs: Kyoto Univ. Seminar
January 22, 2001
- Kosei-Rodosho Wants to Settle All Drug Price Issues in 2002 Reform
January 22, 2001
- Ain Pharmaciez to Become No. 1 Dispensing Pharmacy Operator: Report
January 22, 2001
- SBS, GSK Copromote Antidepressant
January 22, 2001
- Revised GPMSP to Be Enforced from October 1
January 22, 2001
- OTC NEWS IN BRIEF
January 22, 2001
- Santen Markets Betimol for Glaucoma in the US
January 22, 2001
- LDP Hashimoto Group Proposes Copayment of 10% or More for Elderly Healthcare
January 22, 2001
- DIAGNOSTIC NEWS IN BRIEF
January 22, 2001
- Life Science Units of Tomen, Nichimen to Merge into New Company
January 22, 2001
- CPAC Members Fail to Form Consensus on Production, Supply of Blood Preparations
January 22, 2001
- MEDICAL DEVICE NEWS IN BRIEF
January 22, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…